ValiRx : Corporate Video re Clinical Status Q4, 2016

VALIRX PLC

('ValiRx' or 'the Company')

CORPORATE VIDEO RE CLINICAL STATUS Q4, 2016

London, UK., 28 October 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, is pleased to announce that a corporate video regarding the Company's Clinical Status in Quarter 4, 2016, has been issued today and is available for viewing on its websitewww.valirx.comor by using the link below:

https://www.brrmedia.co.uk/broadcasts-embed/580f8edc173df13349c478d1/event/?livelink=true&popup=true

*** ENDS ***

For more information, please contact:

Notes for Editors

ValiRx Plc

ValiRx is a biotechnology oncology focussed companyspecialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in 'precision' medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's three classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market ('AIM') of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.